# Effectiveness of a chatbot in improving the mental wellbeing of health workers in Malawi during the COVID-19 pandemic: A randomized, controlled trial

**Authors:** Eckhard Kleinau, Tilinao Lamba, Wanda Jaskiewicz, Katy Gorentz, Ines Hungerbuehler, Donya Rahimi, Demoubly Kokota, Limbika Maliwichi, Edister Jamu, Alex Zumazuma, Mariana Negrão, Raphael Mota, Yasmine Khouri, Michael Kapps, César González-Blanch, César González-Blanch, César González-Blanch

PMC · DOI: 10.1371/journal.pone.0303370 · PLOS ONE · 2024-05-28

## TL;DR

A chatbot called Vitalk improved mental wellbeing and resilience of health workers in Malawi during the pandemic compared to using internet resources.

## Contribution

First RCT of a mental health app for healthcare workers in Southern Africa during the pandemic with multiple wellbeing outcomes.

## Key findings

- Vitalk reduced depression, anxiety, and burnout in health workers.
- Resilience and resilience-building activities improved significantly more with Vitalk.
- Mental health support is scarce in Malawi, and Vitalk could help fill this gap.

## Abstract

We conducted a randomized, controlled trial (RCT) to investigate our hypothesis that the interactive chatbot, Vitalk, is more effective in improving mental wellbeing and resilience outcomes of health workers in Malawi than the passive use of Internet resources. For our 2-arm, 8-week, parallel RCT (ISRCTN Registry: trial ID ISRCTN16378480), we recruited participants from 8 professional cadres from public and private healthcare facilities. The treatment arm used Vitalk; the control arm received links to Internet resources. The research team was blinded to the assignment. Of 1,584 participants randomly assigned to the treatment and control arms, 215 participants in the treatment and 296 in the control group completed baseline and endline anxiety assessments. Six assessments provided outcome measures for: anxiety (GAD-7); depression (PHQ-9); burnout (OLBI); loneliness (ULCA); resilience (RS-14); and resilience-building activities. We analyzed effectiveness using mixed-effects linear models, effect size estimates, and reliable change in risk levels. Results support our hypothesis. Difference-in-differences estimators showed that Vitalk reduced: depression (-0.68 [95% CI -1.15 to -0.21]); anxiety (-0.44 [95% CI -0.88 to 0.01]); and burnout (-0.58 [95% CI -1.32 to 0.15]). Changes in resilience (1.47 [95% CI 0.05 to 2.88]) and resilience-building activities (1.22 [95% CI 0.56 to 1.87]) were significantly greater in the treatment group. Our RCT produced a medium effect size for the treatment and a small effect size for the control group. This is the first RCT of a mental health app for healthcare workers during the COVID-19 pandemic in Southern Africa combining multiple mental wellbeing outcomes and measuring resilience and resilience-building activities. A substantial number of participants could have benefited from mental health support (1 in 8 reported anxiety and depression; 3 in 4 suffered burnout; and 1 in 4 had low resilience). Such help is not readily available in Malawi. Vitalk has the potential to fill this gap.

## Linked entities

- **Diseases:** anxiety (MONDO:0005618), depression (MONDO:0002050)

## Full-text entities

- **Diseases:** depression (MESH:D003866), COVID-19 (MESH:D000086382), anxiety (MESH:D001007), burnout (MESH:D002055)
- **Chemicals:** Vitalk (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11132445/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11132445/full.md

## References

60 references — full list in the complete paper: https://tomesphere.com/paper/PMC11132445/full.md

---
Source: https://tomesphere.com/paper/PMC11132445